CN103391718A - 取代的吡啶酮-吡啶基化合物 - Google Patents
取代的吡啶酮-吡啶基化合物 Download PDFInfo
- Publication number
- CN103391718A CN103391718A CN201180066860XA CN201180066860A CN103391718A CN 103391718 A CN103391718 A CN 103391718A CN 201180066860X A CN201180066860X A CN 201180066860XA CN 201180066860 A CN201180066860 A CN 201180066860A CN 103391718 A CN103391718 A CN 103391718A
- Authority
- CN
- China
- Prior art keywords
- ketone
- bipyridyl
- methyl
- chloro
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)(*)c1nc(-c2cc(N(C(C)=CC(OC*)=C3*)C3=O)c(*)cn2)c(*)cn1 Chemical compound CC(C)(*)c1nc(-c2cc(N(C(C)=CC(OC*)=C3*)C3=O)c(*)cn2)c(*)cn1 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42007410P | 2010-12-06 | 2010-12-06 | |
US61/420,074 | 2010-12-06 | ||
PCT/US2011/063608 WO2012078684A1 (en) | 2010-12-06 | 2011-12-06 | Substituted pyridinone-pyridinyl compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103391718A true CN103391718A (zh) | 2013-11-13 |
Family
ID=46162793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180066860XA Pending CN103391718A (zh) | 2010-12-06 | 2011-12-06 | 取代的吡啶酮-吡啶基化合物 |
Country Status (13)
Country | Link |
---|---|
US (3) | US20120142709A1 (de) |
EP (2) | EP3469907B1 (de) |
JP (1) | JP5848775B2 (de) |
CN (1) | CN103391718A (de) |
CA (1) | CA2819889C (de) |
DK (1) | DK2648516T3 (de) |
ES (2) | ES2697607T3 (de) |
HR (1) | HRP20181788T1 (de) |
HU (1) | HUE040101T2 (de) |
PL (1) | PL2648516T3 (de) |
PT (1) | PT2648516T (de) |
SI (1) | SI2648516T1 (de) |
WO (1) | WO2012078684A1 (de) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104892499A (zh) * | 2015-06-26 | 2015-09-09 | 江西省科学院应用化学研究所 | 一种2-吡啶酮类衍生物的合成方法 |
CN110678471A (zh) * | 2017-03-16 | 2020-01-10 | 西建卡尔有限责任公司 | Mk2抑制剂及其合成和中间体 |
CN115484952A (zh) * | 2020-03-27 | 2022-12-16 | 阿克拉瑞斯治疗股份有限公司 | 被取代的吡啶酮-吡啶基化合物的方法、组合物和结晶形式 |
WO2023001282A1 (zh) * | 2021-07-23 | 2023-01-26 | 南京明德新药研发有限公司 | 杂环取代的嘧啶衍生物 |
WO2023016535A1 (zh) * | 2021-08-13 | 2023-02-16 | 深圳信立泰药业股份有限公司 | 一种三联吡啶二酮化合物或其盐及其制备方法与应用 |
WO2023125708A1 (zh) * | 2021-12-29 | 2023-07-06 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
WO2023125707A1 (zh) * | 2021-12-29 | 2023-07-06 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
WO2023134765A1 (zh) * | 2022-01-14 | 2023-07-20 | 上海翰森生物医药科技有限公司 | 含五元环类衍生物、其制备方法和应用 |
WO2023217184A3 (zh) * | 2022-05-12 | 2023-12-28 | 上海美悦生物科技发展有限公司 | 取代的吡啶或嘧啶类衍生物及其药物组合物、制备方法和用途 |
WO2024022412A1 (zh) * | 2022-07-28 | 2024-02-01 | 深圳信立泰药业股份有限公司 | 一种式(i)所示的三联吡啶二酮化合物晶型及其制备方法与应用 |
WO2024046327A1 (zh) * | 2022-08-30 | 2024-03-07 | 长春金赛药业有限责任公司 | p38α-MK2抑制剂化合物、药物组合物及其应用 |
WO2024104398A1 (zh) * | 2022-11-16 | 2024-05-23 | 上海美悦生物科技发展有限公司 | 吡啶氮氧化物类衍生物及其药物组合物、制备方法和用途 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105263326B (zh) * | 2013-06-07 | 2018-06-22 | 汇合生命科学股份有限公司 | 甲基/氟-吡啶基-甲氧基取代的吡啶酮-吡啶基化合物及氟-嘧啶基-甲氧基取代的吡啶酮-吡啶基化合物 |
CN104860932B (zh) * | 2015-05-13 | 2018-01-12 | 安阳师范学院 | 一种吡唑啉酮类化合物及其应用 |
AU2020319879A1 (en) * | 2019-07-31 | 2022-02-03 | Aclaris Therapeutics, Inc. | Deuterated MK2 pathway inhibitors and methods of using the same |
TW202237584A (zh) * | 2020-11-23 | 2022-10-01 | 美商阿克拉里斯醫療股份有限公司 | 合成經取代的吡啶酮-吡啶基化合物之方法 |
AU2022252242A1 (en) * | 2021-03-31 | 2023-10-05 | Xinthera, Inc. | Mk2 inhibitors and uses thereof |
AU2022307534A1 (en) | 2021-07-09 | 2024-02-22 | Xinthera, Inc. | Pyridinone mk2 inhibitors and uses thereof |
US20230286950A1 (en) * | 2022-02-04 | 2023-09-14 | Aclaris Therapeutics, Inc. | Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1436172A (zh) * | 2000-06-12 | 2003-08-13 | 卫材株式会社 | 1,2-二氢吡啶化合物及其制备方法和用途 |
CN1578767A (zh) * | 2001-11-22 | 2005-02-09 | 小野药品工业株式会社 | 哌啶-2-酮衍生化合物及包含其作为活性成分的药学组合物 |
WO2005018557A2 (en) * | 2003-08-13 | 2005-03-03 | Pharmacia Corporation | Substituted pyridinones |
CN1646125A (zh) * | 2002-02-14 | 2005-07-27 | 法玛西雅公司 | 作为p38map激酶调节剂的取代吡啶酮类 |
EP1741702A1 (de) * | 2004-04-28 | 2007-01-10 | Ono Pharmaceutical Co., Ltd. | Stickstoffhaltige heterocyclische verbindungen und deren medizinische verwendung |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000017175A1 (en) | 1998-09-18 | 2000-03-30 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
JP2003500403A (ja) | 1999-05-21 | 2003-01-07 | サイオス,インコーポレーテッド | p38キナーゼのインヒビターとしてのインドール型誘導体 |
CA2429605A1 (en) | 2000-11-20 | 2002-05-30 | Scios Inc. | Indol derivative and their use as inhibitors of p38 kinase |
US7314752B2 (en) | 2001-07-19 | 2008-01-01 | Common Sense, Ltd. | Secretion-monitoring article |
WO2003068757A1 (en) * | 2002-02-13 | 2003-08-21 | F. Hoffmann-La Roche Ag | Novel pyridin- and pyrimidin-derivatives |
WO2003091246A1 (en) | 2002-04-26 | 2003-11-06 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
GB0218630D0 (en) | 2002-08-10 | 2002-09-18 | Tanabe Seiyaku Co | Novel compounds |
CA2498111A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
US20070167621A1 (en) | 2003-04-03 | 2007-07-19 | Pharmacia Corporation | Substituted pyrimidinones |
US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
JP2005255675A (ja) | 2004-02-09 | 2005-09-22 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
BRPI0507628A (pt) | 2004-02-11 | 2007-07-03 | Smithkline Beecham Corp | composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto |
AU2006234627C1 (en) | 2005-04-08 | 2009-11-26 | Eisai R & D Management Co., Ltd. | Therapeutic agent for dyskinesia |
WO2007006591A2 (fr) | 2005-07-13 | 2007-01-18 | Bayer Cropscience Sa | Dihalogenation d'hydroxipyridones n,o-disubstituees et leurs utilisations |
WO2007081901A2 (en) | 2006-01-05 | 2007-07-19 | The Scripps Research Institute | Pyrimidinone derivatives as protein kinase inhibitors |
UY30378A1 (es) | 2006-06-02 | 2008-01-02 | Janssen Pharmaceutica Nv | Nuevos derivados de piridinona n-aril y n-heteroaril sustituidos para usar en enfermedades mediadas por mch-1 |
WO2008041090A1 (en) * | 2006-10-06 | 2008-04-10 | Pfizer Limited | Malanin concentrating hormone receptor-1 antagonist pyridinones |
AU2007322608A1 (en) | 2006-11-24 | 2008-05-29 | Takeda Pharmaceutical Company Limited | Heteromonocyclic compound and use thereof |
WO2008073306A1 (en) | 2006-12-07 | 2008-06-19 | Novartis Ag | Organic compounds |
US8198276B2 (en) | 2007-06-06 | 2012-06-12 | Xcovery Holding Company Llc | Kinase inhibitor compounds |
US8003796B2 (en) | 2007-07-17 | 2011-08-23 | Bristol-Myers Squibb Company | Pyridone GPR119 G protein-coupled receptor agonists |
WO2009156484A2 (en) | 2008-06-27 | 2009-12-30 | Novartis Ag | Organic compounds |
US8629158B2 (en) | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
US8618299B2 (en) | 2009-07-01 | 2013-12-31 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof |
WO2011003021A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
US8221753B2 (en) * | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
-
2011
- 2011-12-06 SI SI201131605T patent/SI2648516T1/sl unknown
- 2011-12-06 EP EP18192593.4A patent/EP3469907B1/de active Active
- 2011-12-06 PL PL11847595T patent/PL2648516T3/pl unknown
- 2011-12-06 HU HUE11847595A patent/HUE040101T2/hu unknown
- 2011-12-06 ES ES11847595T patent/ES2697607T3/es active Active
- 2011-12-06 WO PCT/US2011/063608 patent/WO2012078684A1/en active Application Filing
- 2011-12-06 CA CA2819889A patent/CA2819889C/en active Active
- 2011-12-06 DK DK11847595.3T patent/DK2648516T3/da active
- 2011-12-06 JP JP2013543290A patent/JP5848775B2/ja active Active
- 2011-12-06 PT PT11847595T patent/PT2648516T/pt unknown
- 2011-12-06 CN CN201180066860XA patent/CN103391718A/zh active Pending
- 2011-12-06 EP EP11847595.3A patent/EP2648516B1/de active Active
- 2011-12-06 ES ES18192593T patent/ES2873029T3/es active Active
- 2011-12-06 US US13/312,924 patent/US20120142709A1/en not_active Abandoned
-
2014
- 2014-01-07 US US14/149,741 patent/US9365547B2/en active Active
- 2014-01-07 US US14/149,659 patent/US9365546B2/en active Active
-
2018
- 2018-10-30 HR HRP20181788TT patent/HRP20181788T1/hr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1436172A (zh) * | 2000-06-12 | 2003-08-13 | 卫材株式会社 | 1,2-二氢吡啶化合物及其制备方法和用途 |
CN1578767A (zh) * | 2001-11-22 | 2005-02-09 | 小野药品工业株式会社 | 哌啶-2-酮衍生化合物及包含其作为活性成分的药学组合物 |
CN1646125A (zh) * | 2002-02-14 | 2005-07-27 | 法玛西雅公司 | 作为p38map激酶调节剂的取代吡啶酮类 |
WO2005018557A2 (en) * | 2003-08-13 | 2005-03-03 | Pharmacia Corporation | Substituted pyridinones |
EP1741702A1 (de) * | 2004-04-28 | 2007-01-10 | Ono Pharmaceutical Co., Ltd. | Stickstoffhaltige heterocyclische verbindungen und deren medizinische verwendung |
Non-Patent Citations (1)
Title |
---|
ESSA HU,ET,AL.: "Discovery of Aryl Aminoquinazoline Pyridones as Potent, Selective,and Orally Efficacious Inhibitors of Receptor Tyrosine Kinase c-Kit", 《J. MED. CHEM.》 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104892499A (zh) * | 2015-06-26 | 2015-09-09 | 江西省科学院应用化学研究所 | 一种2-吡啶酮类衍生物的合成方法 |
CN110678471A (zh) * | 2017-03-16 | 2020-01-10 | 西建卡尔有限责任公司 | Mk2抑制剂及其合成和中间体 |
CN110678471B (zh) * | 2017-03-16 | 2022-09-13 | 西建卡尔有限责任公司 | Mk2抑制剂及其合成和中间体 |
CN115484952A (zh) * | 2020-03-27 | 2022-12-16 | 阿克拉瑞斯治疗股份有限公司 | 被取代的吡啶酮-吡啶基化合物的方法、组合物和结晶形式 |
WO2023001282A1 (zh) * | 2021-07-23 | 2023-01-26 | 南京明德新药研发有限公司 | 杂环取代的嘧啶衍生物 |
CN116648244A (zh) * | 2021-08-13 | 2023-08-25 | 深圳信立泰药业股份有限公司 | 一种三联吡啶二酮化合物或其盐及其制备方法与应用 |
WO2023016535A1 (zh) * | 2021-08-13 | 2023-02-16 | 深圳信立泰药业股份有限公司 | 一种三联吡啶二酮化合物或其盐及其制备方法与应用 |
CN116648244B (zh) * | 2021-08-13 | 2023-12-15 | 深圳信立泰药业股份有限公司 | 一种三联吡啶二酮化合物或其盐及其制备方法与应用 |
WO2023125708A1 (zh) * | 2021-12-29 | 2023-07-06 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
WO2023125707A1 (zh) * | 2021-12-29 | 2023-07-06 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
WO2023134765A1 (zh) * | 2022-01-14 | 2023-07-20 | 上海翰森生物医药科技有限公司 | 含五元环类衍生物、其制备方法和应用 |
WO2023217184A3 (zh) * | 2022-05-12 | 2023-12-28 | 上海美悦生物科技发展有限公司 | 取代的吡啶或嘧啶类衍生物及其药物组合物、制备方法和用途 |
WO2024022412A1 (zh) * | 2022-07-28 | 2024-02-01 | 深圳信立泰药业股份有限公司 | 一种式(i)所示的三联吡啶二酮化合物晶型及其制备方法与应用 |
WO2024046327A1 (zh) * | 2022-08-30 | 2024-03-07 | 长春金赛药业有限责任公司 | p38α-MK2抑制剂化合物、药物组合物及其应用 |
WO2024104398A1 (zh) * | 2022-11-16 | 2024-05-23 | 上海美悦生物科技发展有限公司 | 吡啶氮氧化物类衍生物及其药物组合物、制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2012078684A1 (en) | 2012-06-14 |
ES2697607T3 (es) | 2019-01-25 |
EP2648516B1 (de) | 2018-09-05 |
HRP20181788T1 (hr) | 2018-12-28 |
US20120142709A1 (en) | 2012-06-07 |
US9365546B2 (en) | 2016-06-14 |
PL2648516T3 (pl) | 2019-04-30 |
CA2819889C (en) | 2020-12-15 |
US9365547B2 (en) | 2016-06-14 |
JP2013544889A (ja) | 2013-12-19 |
EP2648516A1 (de) | 2013-10-16 |
EP2648516A4 (de) | 2014-04-30 |
US20140171449A1 (en) | 2014-06-19 |
PT2648516T (pt) | 2018-11-29 |
DK2648516T3 (da) | 2019-01-02 |
EP3469907B1 (de) | 2021-03-03 |
JP5848775B2 (ja) | 2016-01-27 |
SI2648516T1 (sl) | 2019-01-31 |
CA2819889A1 (en) | 2012-06-14 |
EP3469907A1 (de) | 2019-04-17 |
ES2873029T3 (es) | 2021-11-03 |
US20140171450A1 (en) | 2014-06-19 |
HUE040101T2 (hu) | 2019-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103391718A (zh) | 取代的吡啶酮-吡啶基化合物 | |
JP6838796B2 (ja) | メチル/フルオロ−ピリジニル−メトキシ置換ピリジノン−ピリジニル化合物及びフルオロ−ピリミジニル−メトキシ置換ピリジノン−ピリジニル化合物 | |
JP6783663B2 (ja) | 新規グルタミナーゼ阻害剤 | |
KR102032303B1 (ko) | 아릴- 또는 헤테로아릴-치환된 벤젠 화합물 | |
ES2364328T3 (es) | Compuesto de pirimidina y composición medicinal del mismo. | |
JP5860417B2 (ja) | カテコールo−メチルトランスフェラーゼの阻害剤および精神障害の治療におけるその使用 | |
CN104066718A (zh) | 取代苯化合物 | |
US20130274272A1 (en) | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds | |
JP6298071B2 (ja) | ピリドン誘導体および結核の処置におけるその使用 | |
US8563558B2 (en) | Substituted pyridine urea compounds | |
WO2012078687A1 (en) | Substituted pyrimidine urea compounds | |
JP2022188199A (ja) | Gpr6のテトラヒドロピリドピラジンモジュレーター | |
WO2012078674A1 (en) | Substituted indole/indazole-pyrimidinyl compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131113 |